Plasma and urine cyclic nucleotide levels in patients with acute and
chronic leukemia
M Peracchi, L Lombardi, AT Maiolo, F Bamonti-Catena, V Toschi, O Chiorboli, R Mozzana and EE Polli
Plasma and urine levels of cyclic adenosine 3',5'-monophosphate (cAMP) and
of cyclic guanosine 3',5'-monophosphate (cGMP) were measured in 35 normal
subjects, in 24 patients with nonneoplastic diseases (iron deficiency
anemia, peptic ulcer, and cholelithiasis), and in 50 leukemic patients. The
leukemic group included patients with acute lymphoblastic leukemia, acute
myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous
leukemia. All patients were recently diagnosed and untreated, except for 5
patients with blastic transformation of chronic myelogenous leukemia who
had been previously treated. There were no significant differences in
plasma and urine cyclic nucleotide levels between normal subjects and
patients with nonneoplastic diseases. In leukemic patients, plasma and
urine cAMP levels were similar to those of normal subjects, whereas plasma
and urine cGMP levels were markedly elevated. There were no significant
differences in cGMP values between the various types of leukemia. After
starting treatment, plasma cyclic nucleotide levels were periodically
measured in 21 of the patients with acute leukemia; cGMP levels were
normalized in all the 16 subjects who attained complete remission, whereas
both cAMP and cGMP levels were apparently unaffected in the patients who
did not respond to treatment. This suggests that plasma or urine cGMP could
be used as an additional parameter to monitor the patient's response to
treatment.
Volume 61,
Issue 3,
pp. 429-434,
03/01/1983
Copyright © 1983 by The American Society of Hematology
